

*The AHRS is grateful to the corporate sponsors who support its meetings, programs, and overall organization. They support hair research and advancing the field and are involved in various aspects from hair loss and hair growth, hair care, and hair transplantation.
The information in this handout is current as of May 3, 2019.*

Did you know?



Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology.

BOSLEY

Bosley Inc. provides hair loss and medical hair restoration solutions and has performed more than 300,000 hair transplantation procedures. The company was founded in 1974 and is based in Beverly Hills, California and has surgical offices and consultation offices across the United States. Bosley is a longtime supporter of hair research and the American Hair Research Society and is the founding supporter of its Mentorship Program. More information may be found at: www.bosley.com



Cassiopea has recently completed Phase 2 clinical trials for Clascoterone solution, a novel topical anti-androgen, for the treatment of androgenic alopecia and has completed Phase 3 clinical trials and is filing an NDA soon for Clascoterone 1% cream, a novel topical anti-androgen, for the treatment of acne. Cassiopea is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Our initial focus is on the topical treatment of acne; androgenic alopecia, or AGA; and genital warts. Additional information on our research may be found at cassiopea.com.

CoNCERT Pharmaceuticals Inc.*

Concert is committed to bringing a new treatment option to patients with alopecia areata. At Concert we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative medicines that positively impact patients and address important medical needs. CTP-543, a novel, oral Janus kinase inhibitor for the treatment of alopecia areata, has been granted Fast Track status by the FDA and is currently being evaluated in a Phase 2 clinical trial in adult patients with moderate-to-severe alopecia areata. To learn more about our clinical trials please visit www.concertpharma.com or www.clinicaltrials.gov.

samumed

Samumed is currently enrolling a phase 2/3 multi-center, randomized, double-blind, placebo-controlled, parallel-group study of two doses of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male AGA subjects. The trial is a 54-week study, with 48 weeks of treatment followed by 6 weeks of follow-up. The primary endpoint of the study is the baseline-adjusted absolute non-vellus hair count in the target area by phototrichogram analysis at Week 48 compared to vehicle. Samumed has finished two phase 2 clinical trials with SM04554 for the treatment of androgenetic alopecia (AGA). The primary endpoints were not achieved; however, treatment with SM04554 showed statistically significant increases in two clinically relevant objective outcome measures, compared to vehicle (post-hoc analyses): (1) non-vellus hair counts and density by scalp macrophotography (0.15% SM04554) and (2) follicle counts in both treatment groups (0.15% and 0.25% SM04554) in scalp biopsies.

Samumed is a leader in medical research and development for tissue-level regeneration. With its platform's origins in small-molecule-based Wnt pathway modulation, Samumed develops therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Additional information on our research may be found by visiting www.samumed.com



The NAHRS Seal of Recognition Program was created to inform physicians and consumers about products whose quality and effectiveness are beneficial in some aspect in promoting healthy hair or scalp, in diagnosing or treating hair or scalp disease, in diagnosing or treating hair loss, or in stimulating or inhibiting hair growth.

Seal Product Directory

HairMax LaserComb - The HairMax LaserComb is available in 3 models and has been clinically proven to increase hair counts in men and women with androgenetic alopecia.



Nioxin DiaMax with HTX™, is proven to increase the thickness of each existing hair strand."



Keranique Lift & Repair Treatment Spray - "for anti-frizz, protection from heat damage, strengthens the hair fiber, and diffusion into the cuticle"



Pantene Pro-V Daily Thickening Treatment - "Pantene's Daily Thickening Treatment thickens individual hair fibers."



Pantene Pro-V Medium-Thick, 4-product regimen - "long lasting smoothness," with "long lasting" defined as >24 hours

